This is in line with other clinical studies that demonstrated similar numbers of the ERBB2 mutation, alteration, and co-occurring mutations and alterations in NSCLC patients, with incidences of 1 to 4%, from 2 to 10% and up to 5.5%, respectively [55,56]. Here, ERBB2 is linked to non-small cell lung carcinoma.